AAV4 VP3 Antibody [Janelia Fluor® 549]

Novus Biologicals | Catalog # NB100-93576JF549

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

Non-species specific, Virus

Applications

Western Blot

Label

Janelia Fluor 549

Antibody Source

Polyclonal Rabbit IgG
View all AAV4 VP3 Primary Antibodies »

Product Specifications

Immunogen

Directed against a synthetic peptide within residues 450-475 of 81 kDa capsid VP3 protein of AAV 4.

Reactivity Notes

Virus

Specificity

Adeno-Associated Virus (AAV)

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for AAV4 VP3 Antibody [Janelia Fluor® 549]

Application
Recommended Usage

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: AAV4 VP3

Adeno-associated virus (AAV) is a small, non-enveloped single-stranded DNA virus belonging to the Pavoviridae family in the genus Dependoparvovirus, which requires a helper virus in order to replicate (1-3). The AAV genome consists of a rep and cap gene which are flanked by inverted terminal repeats (ITRs) (1-4). The rep gene encodes for AAV's non-structural proteins that function in replication, packaging, and integration (2-4). The cap gene encodes the structural proteins (VP1, VP2, VP3) that form the viral capsid made up of 60 protein subunits (2-4). Recombinant AAV vectors are generated by replacing the rep and cap genes and inserting a promoter, followed by a transgene, and then a poly-A (pA) tail, flanked by ITRs (3-4). Recombinant vectors are then packaged by providing the rep and cap genes in trans and helper genes for AAV replication (3). AAV vectors have been studied for their potential in human gene therapy and are considered a safe platform given their low immunogenicity and that they are not associated with any known diseases (1-4). Additionally, recombinant AAV vectors are typically non-integrating (1). There are 13 identified human and non-human primate AAV serotypes and over 100 natural AAV variants (2-4). The AAV serotypes are further classified into six clades (A-F) and two clonal isolates (AAV4 and AAV5) according to the VP1 amino acid (aa) sequence (3). These AAV serotypes share ~65-99% sequence identity and ~95-99% structural identity (3). Research has shown that the different AAV serotypes have varying tissue tropism and transduction efficiency based on tissue origin (2). For instance, AAV8 and AAV9 are optimal for transduction in the liver, while AAV2 is ideal for the kidney (2). AAV2 is the best characterized and most commonly used AAV serotype in preclinical studies and clinical trials (4). AAV vectors have been employed in a number oncology models for their ability to carry and deliver a variety of factors including anti-angiogenic genes, suicide genes, tumor suppressors, cytokines, and monoclonal antibodies (4). Advances in engineering AAV vectors and combining AAV gene delivery with other treatment modalities, like chemotherapeutics, is promising for the future of human gene therapy (2-4).

References

1. Zengel J, Carette JE. Structural and cellular biology of adeno-associated virus attachment and entry. Adv Virus Res. 2020;106:39-84. https://doi.org/10.1016/bs.aivir.2020.01.002

2. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316-327. https://doi.org/10.1016/j.ymthe.2006.05.009

3. Drouin LM, Agbandje-McKenna M. Adeno-associated virus structural biology as a tool in vector development. Future Virol. 2013;8(12):1183-1199. https://doi.org/10.2217/fvl.13.112

4. Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287-301. https://doi.org/10.1016/j.jconrel.2016.01.001

Alternate Names

Adenovirus 4, AdV 4

Additional AAV4 VP3 Products

Product Documents for AAV4 VP3 Antibody [Janelia Fluor® 549]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for AAV4 VP3 Antibody [Janelia Fluor® 549]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews for AAV4 VP3 Antibody [Janelia Fluor® 549]

There are currently no reviews for this product. Be the first to review AAV4 VP3 Antibody [Janelia Fluor® 549] and earn rewards!

Have you used AAV4 VP3 Antibody [Janelia Fluor® 549]?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies